These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 11483881)

  • 1. Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure.
    Qiu C; Ding SS; Hess P; Clozel JP; Clozel M
    J Cardiovasc Pharmacol; 2001 Aug; 38(2):317-24. PubMed ID: 11483881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
    Qiu CB; Qiu CS; Hess P; Clozel JP; Clozel M
    Acta Pharmacol Sin; 2001 Jun; 22(6):541-8. PubMed ID: 11747762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets during endotoxic shock.
    Chin A; Radhakrishnan J; Fornell L; John E
    J Pediatr Surg; 2002 Mar; 37(3):482-7. PubMed ID: 11877672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets.
    Chin A; Radhakrishnan J; Fornell L; John E
    J Pediatr Surg; 2001 Dec; 36(12):1824-8. PubMed ID: 11733915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction.
    Clozel M; Qiu C; Qiu CS; Hess P; Clozel JP
    J Am Coll Cardiol; 2002 Jan; 39(1):142-7. PubMed ID: 11755300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism.
    Wada A; Tsutamoto T; Ohnishi M; Sawaki M; Fukai D; Maeda Y; Kinoshita M
    Circulation; 1999 Feb; 99(4):570-7. PubMed ID: 9927406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.
    Torre-Amione G; Young JB; Durand J; Bozkurt B; Mann DL; Kobrin I; Pratt CM
    Circulation; 2001 Feb; 103(7):973-80. PubMed ID: 11181472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function.
    Yamauchi-Kohno R; Miyauchi T; Hoshino T; Kobayashi T; Aihara H; Sakai S; Yabana H; Goto K; Sugishita Y; Murata S
    Circulation; 1999 Apr; 99(16):2171-6. PubMed ID: 10217659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
    Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
    Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock.
    Konrad D; Oldner A; Rossi P; Wanecek M; Rudehill A; Weitzberg E
    Crit Care Med; 2004 May; 32(5):1192-9. PubMed ID: 15190972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of endothelin receptors ET(A) and ET(B) blockade on renal haemodynamics in normal rats and in rats with experimental congestive heart failure.
    Abassi Z; Francis B; Wessale J; Ovcharenko E; Winaver J; Hoffman A
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():245S-248S. PubMed ID: 12193096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal effects of high-dose natriuretic peptide receptor blockade in rats with congestive heart failure.
    Zhang PL; Mackenzie HS; Totsune K; Troy JL; Brenner BM
    Circ Res; 1995 Dec; 77(6):1240-5. PubMed ID: 7586237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure.
    Mulder P; Richard V; Bouchart F; Derumeaux G; Münter K; Thuillez C
    Cardiovasc Res; 1998 Sep; 39(3):600-8. PubMed ID: 9861302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. sGC stimulation totally reverses hypoxia-induced pulmonary vasoconstriction alone and combined with dual endothelin-receptor blockade in a porcine model.
    Lundgren J; Kylhammar D; Hedelin P; Rådegran G
    Acta Physiol (Oxf); 2012 Nov; 206(3):178-94. PubMed ID: 22682645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure.
    Francis B; Winaver J; Karram T; Hoffman A; Abassi Z
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S54-8. PubMed ID: 15838359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.
    Cotter G; Kiowski W; Kaluski E; Kobrin I; Milovanov O; Marmor A; Jafari J; Reisin L; Krakover R; Vered Z; Caspi A
    Eur J Heart Fail; 2001 Aug; 3(4):457-61. PubMed ID: 11511432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?
    Spieker LE; Noll G; Ruschitzka FT; Lüscher TF
    J Am Coll Cardiol; 2001 May; 37(6):1493-505. PubMed ID: 11345356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure.
    Kos T; Pacher R; Wimmer A; Bojic A; Hülsmann M; Frey B; Mayer G; Yilmaz N; Skvarilova L; Spinar J; Vitovec J; Toman J; Woloszcuk W; Stanek B
    Wien Klin Wochenschr; 1998 Feb; 110(3):89-95. PubMed ID: 9553203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual endothelin receptor blockade with tezosentan markedly attenuates hypoxia-induced pulmonary vasoconstriction in a porcine model.
    Hedelin P; Kylhammar D; Rådegran G
    Acta Physiol (Oxf); 2012 Mar; 204(3):419-34. PubMed ID: 21726419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models.
    Ryu SM; Kim HJ; Cho KR; Jo WM
    J Korean Med Sci; 2009 Oct; 24(5):782-8. PubMed ID: 19794971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.